Cytokinetics (CYTK) financial statements
Cytokinetics reported revenue of $88M in fiscal 2025, down 2.1% a year over 9 years.
Net income was -$785M and the operating margin -695.4%, against 17.6% in 2016.
Free cash flow was -$535M.
The diluted share count rose 182% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Cytokinetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $106M | $13M | $32M | $27M | $56M | $70M | $95M | $8M | $18M | $88M |
| Research and development | $60M | $90M | $89M | $86M | $97M | $160M | $241M | $330M | $339M | $416M |
| Selling, general and admin | $28M | $36M | $31M | $40M | $53M | $97M | $178M | $174M | $215M | $284M |
| Operating income | $19M | -$113M | -$89M | -$99M | -$94M | -$186M | -$324M | -$496M | -$536M | -$612M |
| Interest expense | $3M | $3M | $4M | $7M | $16M | $16M | $19M | $28M | $38M | $46M |
| Pre-tax income | $16M | -$128M | -$106M | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $16M | -$128M | -$106M | -$122M | -$127M | -$215M | -$389M | -$526M | -$590M | -$785M |
| EPS (diluted) | $0.39 | -$2.59 | -$1.95 | -$2.11 | -$1.97 | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Diluted shares | 43M | 49M | 54M | 58M | 65M | 77M | 90M | 97M | 112M | 120M |
| Operating margin | 17.6% | -848.3% | -282.3% | -368.0% | -168.3% | -264.5% | -342.8% | -6589.7% | -2902.7% | -695.4% |
| Net margin | 15.5% | -955.9% | -337.4% | -452.9% | -228.0% | -305.7% | -411.2% | -6988.6% | -3191.1% | -891.6% |
Balance sheet
Fiscal years, from Cytokinetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $164M | $285M | $199M | $268M | $501M | $624M | $829M | $655M | $1.2B | $1.2B |
| Receivables | $24,000 | $1M | $2M | $5M | $4M | $52M | $147,000 | $1M | $17M | $18M |
| Inventory | — | — | — | — | — | — | — | — | — | $0 |
| Total current assets | $159M | $274M | $208M | $234M | $474M | $536M | $795M | $628M | $1.1B | $917M |
| Property, plant and equipment | $4M | $4M | $3M | $5M | $13M | $73M | $80M | $69M | $66M | $79M |
| Total assets | $170M | $295M | $211M | $290M | $534M | $841M | $1.0B | $824M | $1.4B | $1.4B |
| Total current liabilities | $33M | $32M | $22M | $26M | $31M | $72M | $85M | $103M | $180M | $202M |
| Long-term debt | $27M | $32M | $40M | $45M | $46M | $47M | $64M | $58M | $93M | $246M |
| Total liabilities | $76M | $185M | $185M | $301M | $420M | $597M | $1.1B | $1.2B | $1.5B | $2.1B |
| Shareholders' equity | $94M | $110M | $26M | -$11M | $113M | $244M | -$108M | -$386M | -$135M | -$660M |
| Net debt | -$37M | -$93M | $157,000 | $9M | -$37M | -$65M | -$814,000 | -$45M | $10M | $165M |
Cash flow
Fiscal years, from Cytokinetics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $37M | -$102M | -$101M | -$91M | $9M | -$143M | -$300M | -$414M | -$396M | -$510M |
| Capital spending | $2M | $3M | $889,000 | $3M | $11M | $49M | $11M | $1M | $4M | $25M |
| Free cash flow | $35M | -$105M | -$102M | -$94M | -$2M | -$191M | -$311M | -$416M | -$400M | -$535M |
| Stock-based compensation | $7M | $9M | $10M | $11M | $18M | $27M | $48M | $72M | $98M | $112M |
| Net borrowing | — | — | — | — | $0 | $0 | -$48M | $0 | -$9M | -$11M |
| Free cash flow margin | 33.3% | -782.7% | -324.1% | -348.1% | -3.8% | -271.8% | -328.6% | -5521.2% | -2164.1% | -607.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CYTK.
Open CYTK in InvestinglyQuestions
What was Cytokinetics's revenue in 2025?
$88M in fiscal 2025, from its 10-K filing.
How much free cash flow does Cytokinetics generate?
-$535M in fiscal 2025 (operating cash flow minus capital spending).
From Cytokinetics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.